Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated traditional Chinese and Western medicine for myocardial remodeling after acute myocardial infarction
ChiCTR2100048633Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qishen yiqi dripping pills and danlou in myocardial infarction (MI) (4 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Left ventricular end-diastolic volume and Left ventricular end-systolic volume. Started Sep 2021; status: recruiting.
02
Drugs
qishen yiqi dripping pillsdanlou
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100048633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048633.